Baiyunshan(00874.HK): Cefaclor Sustained-release Tablets (II) of Its Branch Obtains Drug Registration Certificate

NewTimeSpace News: On June 10, 2026, Baiyunshan (00874.HK) issued an announcement stating that Baiyunshan General Pharmaceutical Factory, its branch company, has obtained the Drug Registration Certificate for Cefaclor Sustained-release Tablets (II) from the National Medical Products Administration.

As a second-generation cephalosporin, this drug is clinically indicated for acute bronchitis, pneumonia, pharyngitis, tonsillitis, lower urinary tract infections, skin and soft tissue infections and other conditions. Its original developer is Eli Lilly and Company of the United States. The drug was approved for launch in the US in 1996 and gained domestic approval in China in 2002.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.